Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Astrazeneca Plc (AZN.LN)

Astrazeneca Plc (AZN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial Business Wire - Tue Jun 2, 7:00AM CDT

Switching to camizestrant led to a 99% median reduction in total ctDNA vs. a 64% increase for patients who remained on standard of care 51% of patients...

AZN : 185.95 (+2.28%)
AZN.LN : 13,857.998 (+2.24%)
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial Business Wire - Mon Jun 1, 7:00AM CDT

Positive overall survival trend in favor of STRIDE regimen with lenvatinib and TACE

AZN : 185.95 (+2.28%)
AZN.LN : 13,857.998 (+2.24%)
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer Business Wire - Thu May 28, 8:18PM CDT

Based on POTOMAC Phase III trial results which showed a 32% reduction in the risk of high-risk disease recurrence, progression or death after one year of IMFINZI added to BCG vs. BCG alone

AZN : 185.95 (+2.28%)
AZN.LN : 13,857.998 (+2.24%)
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates Business Wire - Fri May 22, 9:16AM CDT

AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with an unprecedented median overall survival...

AZN : 185.95 (+2.28%)
AZN.LN : 13,857.998 (+2.24%)
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026 Business Wire - Fri May 22, 6:00AM CDT

EMERALD-3 late-breaking presentation will showcase benefit of IMFINZI ® (durvalumab) and IMJUDO ® (tremelimumab-actl) in early liver...

AZN : 185.95 (+2.28%)
AZN.LN : 13,857.998 (+2.24%)
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension Business Wire - Mon May 18, 6:00AM CDT

Approval based on BaxHTN Phase III results showing statistically significant and clinically meaningful reduction in systolic blood pressure in patients with uncontrolled or resistant hypertension ...

AZN : 185.95 (+2.28%)
AZN.LN : 13,857.998 (+2.24%)
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer Business Wire - Fri May 15, 8:52PM CDT

Approved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on DESTINY-Breast05 Phase III trial...

AZN : 185.95 (+2.28%)
AZN.LN : 13,857.998 (+2.24%)
Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial Business Wire - Thu May 14, 6:00AM CDT

Perioperative IMFINZI plus IMJUDO® (tremelimumab-actl) and neoadjuvant EV showed a statistically significant and clinically meaningful improvement in event-free survival and a favorable trend for overall...

AZN : 185.95 (+2.28%)
AZN.LN : 13,857.998 (+2.24%)
TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer Business Wire - Thu Apr 30, 8:42PM CDT

ODAC overwhelming majority voted that TRUQAP plus abiraterone and ADT demonstrated a favorable benefit risk profile for patients based on the CAPItello-281 Phase III trial results ...

AZN : 185.95 (+2.28%)
AZN.LN : 13,857.998 (+2.24%)
AstraZeneca results: Q1 2026 Business Wire - Wed Apr 29, 6:00AM CDT

Strong revenue growth and positive readouts from high-value NMEs reinforce confidence in 2030 ambition

AZN : 185.95 (+2.28%)
AZN.LN : 13,857.998 (+2.24%)

Barchart Exclusives

GitLab Shares Sink After Layoff News. Why Analysts Still See Massive Upside. Barchart - 1 hour ago
GitLab's sharp selloff may be masking a stronger business built on improving margins, AI expansion, and a growing cash position. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.